European Journal of Medicinal Chemistry, Год журнала: 2022, Номер 246, С. 114971 - 114971
Опубликована: Ноя. 28, 2022
Язык: Английский
Molecular Cancer, Год журнала: 2023, Номер 22(1)
Опубликована: Июль 6, 2023
Abstract Breast cancer is the second leading cause of death for women worldwide. The heterogeneity this disease presents a big challenge in its therapeutic management. However, recent advances molecular biology and immunology enable to develop highly targeted therapies many forms breast cancer. primary objective therapy inhibit specific target/molecule that supports tumor progression. Ak strain transforming, cyclin-dependent kinases, poly (ADP-ribose) polymerase, different growth factors have emerged as potential targets subtypes. Many drugs are currently undergoing clinical trials, some already received FDA approval monotherapy or combination with other treatment yet achieve promise against triple-negative (TNBC). In aspect, immune has come up promising approach specifically TNBC patients. Different immunotherapeutic modalities including immune-checkpoint blockade, vaccination, adoptive cell transfer been extensively studied setting cancer, especially approved blockers chemotherapeutic treat several trials ongoing. This review provides an overview developments advancements immunotherapies treatment. successes, challenges, prospects were critically discussed portray their profound prospects.
Язык: Английский
Процитировано
267
Molecular Biomedicine, Год журнала: 2022, Номер 3(1)
Опубликована: Дек. 21, 2022
The PI3K/AKT/mTOR and RAF/MEK/ERK pathways are commonly activated by mutations chromosomal translocation in vital targets. signaling pathway is dysregulated nearly all kinds of neoplasms, with the component this alternations. cascades used to conduct from cell surface nucleus mediate gene expression, cycle processes apoptosis. RAS, B-Raf, PI3K, PTEN frequent upstream alternative sites. These resulted growth downregulated two interact each other participate tumorigenesis. alterations suppress activity via AKT phosphorylation RAS inhibition. Several inhibitors targeting major components these have been supported FDA. Dozens agents attracted great attention assessed clinical trials. combination small molecular traditional regimens has also explored. Furthermore, dual provide new insight into antitumor activity. This review will further comprehensively describe genetic normal patients tumor discuss role targeted malignant neoplasm therapy. We hope promote a comprehensive understanding facilitating tumors help direct drug selection for
Язык: Английский
Процитировано
118
Molecular Cancer, Год журнала: 2023, Номер 22(1)
Опубликована: Сен. 2, 2023
Immunotherapy has recently emerged as a treatment strategy which stimulates the human immune system to kill tumor cells. Tumor immunotherapy is based on editing, enhances antigenicity of cells and increases tumoricidal effect It also suppresses immunosuppressive molecules, activates or restores function, anti-tumor responses, inhibits growth f cell. This offers possibility reducing mortality in triple-negative breast cancer (TNBC).Immunotherapy approaches for TNBC have been diversified recent years, with breakthroughs this entity. Research checkpoint inhibitors (ICIs) made it possible identify different molecular subtypes formulate individualized schedules. review highlights unique microenvironment integrates analyzes advances ICI therapy. discusses strategies combination ICIs chemotherapy, radiation therapy, targeted emerging methods such nanotechnology, ribonucleic acid vaccines, gene Currently, numerous ongoing completed clinical trials are exploring utilization conjunction existing modalities TNBC. The objective these investigations assess effectiveness various combined determine most effective regimens patients TNBC.This provides insights into used overcome drug resistance immunotherapy, explores directions development
Язык: Английский
Процитировано
115
Advanced Science, Год журнала: 2023, Номер 10(15)
Опубликована: Март 23, 2023
Abstract Gut microbiota‐derived metabolites are key hubs connecting the gut microbiome and cancer progression, primarily by remodeling tumor microenvironment regulating signaling pathways in cells multiple immune cells. The use of microbial radiotherapy chemotherapy mitigates severe side effects from treatment improves efficacy treatment. Immunotherapy combined with effectively activates system to kill tumors overcomes drug resistance. Consequently, various novel strategies have been developed modulate metabolites. Manipulation genes involved metabolism using synthetic biology approaches directly affects levels metabolites, while fecal transplantation phage affect altering composition microbiome. However, some harbor paradoxical functions depending on context (e.g., type cancer). Furthermore, metabolic microorganisms certain anticancer drugs such as irinotecan gemcitabine, render ineffective or exacerbate their adverse effects. Therefore, a personalized comprehensive consideration patient's condition is required when employing treat cancer. purpose this review summarize correlation between cancer, provide fresh ideas for future scientific research.
Язык: Английский
Процитировано
95
Pathology - Research and Practice, Год журнала: 2023, Номер 249, С. 154736 - 154736
Опубликована: Авг. 3, 2023
Язык: Английский
Процитировано
78
International Immunopharmacology, Год журнала: 2023, Номер 123, С. 110714 - 110714
Опубликована: Июль 29, 2023
Язык: Английский
Процитировано
56
Cell Communication and Signaling, Год журнала: 2023, Номер 21(1)
Опубликована: Авг. 3, 2023
Abstract Breast cancer exhibits the highest global incidence among all tumor types. Regardless of type breast cancer, metastasis is a crucial cause poor prognosis. Anoikis, form apoptosis initiated by cell detachment from native environment, an outside-in process commencing with disruption cytosolic connectors such as integrin-ECM and cadherin-cell. This subsequently leads to intracellular cytoskeletal signaling pathway alterations, ultimately activating caspases initiating programmed death. Development anoikis-resistant phenotype critical initial step in metastasis. employs series stromal alterations suppress anoikis cells. Comprehensive investigation resistance mechanisms can inform strategies for preventing regressing metastatic cancer. The present review first outlines physiological anoikis, elucidating pathways, cytoskeleton, protein targets that transpire outside upon adhesion loss normal specific induced pathological changes various spatial structures during development are also discussed. Additionally, genetic loci altered summarized. Finally, micro-RNAs targeted drugs reported literature concerning compiled, keratocin being most functionally comprehensive.
Язык: Английский
Процитировано
47
Biomolecules, Год журнала: 2023, Номер 13(1), С. 93 - 93
Опубликована: Янв. 2, 2023
Breast cancer is the most commonly diagnosed in women. The high incidence of breast cancer, which continuing to rise, makes treatment a significant challenge. PI3K-AKT pathway and its downstream targets influence various cellular processes. In recent years, mounting evidence has shown that natural products synthetic drugs targeting signaling have potential treat cancer. this review, we discuss role occurrence development highlight PI3K-AKT-targeting clinical trials for
Язык: Английский
Процитировано
41
Breast Cancer, Год журнала: 2024, Номер 31(4), С. 539 - 551
Опубликована: Апрель 17, 2024
Triple-negative breast cancer (TNBC) is a highly heterogeneous tumor lacking estrogen receptor (ER), progesterone (PR), and human epidermal growth factor 2 (HER2) expression. It has higher aggressiveness metastasis than other subtypes, with limited effective therapeutic strategies, leading to poor prognosis. The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) signaling pathway prevalently over-activated in cancers contributes (BC) growth, survival, proliferation, angiogenesis, which could be an interesting target. This review summarizes the PI3K/AKT/mTOR activation mechanism TNBC discusses relationship between its various subtypes. We also report latest clinical studies on inhibitors related this for treating TNBC. Our issues that need addressed application these inhibitors.
Язык: Английский
Процитировано
37
Cancers, Год журнала: 2024, Номер 16(8), С. 1554 - 1554
Опубликована: Апрель 18, 2024
Cancer is a life-threatening disease and one of the leading causes death worldwide. Despite significant advancements in therapeutic options, most available anti-cancer agents have limited efficacy. In this context, natural compounds with diverse chemical structures been investigated for their multimodal properties. Curcumin polyphenol isolated from rhizomes Curcuma longa has widely studied its anti-inflammatory, anti-oxidant, effects. acts on regulation different aspects cancer development, including initiation, metastasis, angiogenesis, progression. The phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT) pathway key target therapy, since it implicated proliferation, cell survival. found to inhibit PI3K/Akt tumor cells, primarily via mediators, growth factors, protein kinases, cytokines. This review presents potential curcumin malignancies, such as glioblastoma, prostate breast cancer, head neck cancers, through targeting signaling pathway.
Язык: Английский
Процитировано
27